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Predicting malignant progression 
in clinically high-risk lesions by 
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grading
Zuraiza Mohamad Zaini  1,2, Helen McParland3, Henrik Møller4, Kate Husband3 & 
Edward W. Odell1
The value of image cytometry DNA ploidy analysis and dysplasia grading to predict malignant 
transformation has been determined in oral lesions considered to be at ‘high’ risk on the basis of 
clinical information and biopsy result. 10-year follow up data for 259 sequential patients with oral 
lesions clinically at ‘high’ risk of malignant transformation were matched to cancer registry and local 
pathology database records of malignant outcomes, ploidy result and histological dysplasia grade. 
In multivariate analysis (n = 228 patients), 24 developed carcinoma and of these, 14 prior biopsy 
samples were aneuploid. Aneuploidy was a significant predictor (hazard ratio 7.92; 95% CI 3.45, 18.17) 
compared with diploidy (p < 0.001). The positive predictive value (PPV) for severe dysplasia was 50% 
(95% CI 31.5, 68.5) and for aneuploid lesions, 33.3% (95% CI 19.0, 47.6). Combined DNA aneuploidy 
and severe dysplasia increased PPV to 56.3% (95% CI 31.9, 80.6). Diploid-tetraploid and non-dysplastic 
status had high negative predictive values (NPV) of 94.6% (95% CI 91.4, 97.8) and 99.17% (95% CI 97.4, 
100.8) respectively. DNA ploidy predicts malignant transformation well and combining it with dysplasia 
grading gave the highest predictive value. The predictive values reported here exceed those from other 
investigations to date.
Squamous carcinoma of the mouth is a relatively rare cancer but one with a poor prognosis and whose treatment 
carries a high morbidity. One major reason for the high cancer burden is that most patients present at late stage1.
A proportion of oral squamous carcinomas arise in pre-existing disorders called the oral potentially malignant 
disorders (OPMD)2,3. OPMD are much more prevalent than carcinomas and identifying them allows patients 
both surveillance for early diagnosis and treatment to prevent carcinoma developing4.
Among OPMD, leukoplakia, erythroplakia5 and speckled leukoplakia (white, red and mixed mucosal patches 
respectively) carry a high risk of malignant transformation and their recognition allows early diagnosis of car-
cinomas and interventions to prevent malignant transformation. However, the great majority of these oral red 
and white patches never undergo malignant transformation4,6 despite being widely described as ‘high-risk’ and 
identifying those at sufficient risk to benefit from surgery is insufficiently accurate for clinical practice; many 
patients are under lifelong review for lesions of no significance and others risk morbidity from repeated biopsy 
and unnecessary excisions.
The current reference standard test used clinically to predict risk of malignant transformation is the presence 
and grade of dysplasia seen histologically in a biopsy specimen. However, the grading of dysplasia is subjective 
and has poor reproducibility7 and in several large studies has proved a poor predictor of outcome8–10. Dysplasia 
may regress11–13 and non-dysplastic lesions may transform6,8,14. Better methods are therefore required.
DNA aneuploidy, a state of having abnormal total nuclear DNA content, is a known hallmark of cancer, drives 
carcinogenesis and has proven ability to predict development of cancer at several body sites. The predictive value 
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of DNA aneuploidy for malignant transformation in OPMDs has previously been investigated in small case 
series15–18, by association with dysplasia grade19–23 and its correlation with other clinical parameters24,25.
We have recently proposed that DNA image cytometry (ICM) ploidy analysis is the best predictor of malig-
nant transformation for OPMDs. In a large series of patients with red and white lesions, including those of low 
and minimal risk representative of referrals from primary care, we showed that DNA ICM ploidy analysis had 
high positive predictive value for malignant transformation and detected non-dysplastic lesions at risk that would 
otherwise have been missed using routine methods26. This study established the value of DNA ploidy analysis in 
a population with an overall low incidence and risk of development of oral carcinoma.
The aims of this new study were to establish the predictive value of DNA ploidy analysis in a consecutive series 
of patients considered to be at higher risk of developing carcinoma, on the basis of specialist clinical evaluation 
and biopsy. Further differences from previous studies include the use of two different sample preparation meth-
ods, analysis using improved software, and a near sequential study population with more complete follow-up data 
and reduced selection bias.
Results
Patient characteristics, samples and follow up. From the 259 consecutive patients identified from the 
archive, 31 were excluded leaving 228 patients in the analysis. Reasons for exclusions and outcomes are shown 
in a STARD diagram in Fig. 1. Four patients were excluded for other causative factors being identified on review, 
requiring a change of diagnosis.
Eligible patients n=259
Previous OSCC n=8
Changed diagnosis n=4 
Eligible patients n=247
Cancer Registration Data DNA ploidy analysis
Patients untraceable
n=7
Ploidy analysis not possible
- Missing block n-1
- No tissue left n=6
- Insufficient nuclei n=3
Patients with DNA ploidy 
results for index biopsy 
n=237
Patients with both cancer status and DNA ploidy in diagnosis
n=228
Oral 
cancer 
n=24
UADT 
cancer 
n=2
Cancer diagnosed < 2 
weeks after biopsy n=2
Patients with cancer 
registration and follow up  
n=238
Remote 
cancer 
n=22
No
cancer 
n=180
Figure 1. STARD diagram showing recruitment and reasons for exclusion of patients. OSCC = oral squamous 
cell carcinoma; UADT = upper aerodigestive tract.
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The clinical presentations for the study population are shown in Table 1. The majority were white lesions of 
tongue, buccal mucosa or gingiva. Thirteen patients had other presentations or reasons for biopsy; ulceration in 
3 cases, induration in 2, submucous fibrosis in 1. In the remainder, no specific clinical presentation was provided 
and biopsy was performed for purposes such as monitoring prior dysplasia or to exclude possible carcinoma and 
no further data was available. One hundred and nine (47.8%) of patients were smokers, 19 (8.3%) ex- smokers and 
no data was available for 56 (24.6%) patients.
The mean age of the patients at time of diagnosis of the index lesion was 55 years (SD 13.9 years) and 122 were 
male (53.5%) and 106 female (46.5%). The follow up period ranged from 5 to 9.6 years (mean = 7.61, SD = 2.69). 
Malignant transformation to oral squamous carcinoma occurred in 24 patients, and in 9 of these the carcinoma 
developed less than 6 months after index specimen. This subgroup was analysed separately. Details of the study 
population, dysplasia and ploidy diagnosis, subgrouped by time to transformation are shown in Table 2.
Multiple samples were available from 25 patients, from whom further specimens had been taken during the 
inclusion period of 2004-7; 10 patients had a second biopsy, ten had three biopsies, three patients had four and 
two had a total of seven biopsies.
Nuclear extraction method comparison. Ten samples that had sufficient tissues were included for 
comparison of nuclear extraction methods. Using the newer method, more lymphocyte nuclei were acquired 
(p = 0.01) and fewer fibroblast nuclei were isolated (p = 0.03) but numbers of these reference control diploid cells 
were always far in excess of the number required for analysis (data not shown). There was no difference between 
the numbers of nuclei excluded as defective. The coefficient of variaton (CV) of the diploid peak in DNA ploidy 
histograms was better (lower) using the routine method (p = 0.007, range 1.34 to 2.57) than the newer method 
(range 1.72 and 3.75) but all values were well below the 5% value required for diagnosis. There was complete 
diagnostic agreement between final results obtained with both methods (κ value = 1.00) and samples analysed by 
both methods were included in the final analysis.
DNA ploidy and dysplasia. Of the 228 samples, 42 (18.4%) were DNA aneuploid, 3 (1.3%) DNA tetraploid 
and 183 (80.3%) DNA diploid. DNA aneuploidy was diagnosed mainly in lesions with moderate (36%) and severe 
(38%) epithelial dysplasia. Almost all non-dysplastic lesions (99.2%) were diploid.
Site
White lesion/
keratosis n (%)
Speckled n 
(%)
Red n 
(%) Total n (%)
Total nodular or 
verrucous n (%)
Tongue 56 (24.6) 4 (1.6) 1 (0.4) 61 (26.8) 3 (1.3)
Buccal mucosa 42 (18.4) 2 (0.9) 3 (1.3) 47 (20.6) 2 (0.9)
Gingiva and/or alveolar ridge 30 (13.2) 1 (0.4) — 31 (13.6) 2 (0.9)
Soft palate 17 (7.5) 1 (0.4) — 18 (7.9) 1 (0.4)
Floor of mouth 13 (5.7) — 1 (0.4) 14 (6.1) —
Retromolar and fauces 13 (5.7) 1 (0.4) — 14 (6.1) —
Multifocal 24 (10.5) 6 (2.6) — 30 (13.2) 5 (2.2)
Miscellaneous and unknown* 13 (5.7) — — 13 (5.7)
Total 208 (91.2) 15 (6.6) 5 (2.2) 228 (100) 13 (5.7)
Table 1. Clinical descriptors of patient presentations, determined from multiple biopsy specimens when 
present. *Unknown, see text.
Including transformation within 
6 months of index lesion
Excluding transformation within 6 
months of index lesion
n (%)
Malignant 
transformation n (%) n (%)
Malignant 
transformation n (%)
Total patients 228 24 (10.5) 219 15 (6.9)
Age (years) Mean (SD) 55 (13.9) 60.4 (10.4) 55 (14.1) 62.2 (11.6)
Gender
Male 122 (53.5) 11 (45.8) 118 (53.9) 7 (46.7)
Female 106 (46.5) 13 (54.2) 101 (46.1) 8 (53.3)
Dysplasia grade
None 121 (53.1) 1 (4.2) 121 (55.3) 1 (6.7)
Mild 47 (20.6) 2 (8.3) 47 (21.5) 2 (13.3)
Moderate 32 (14.0) 7 (29.2) 30 (13.7) 5 (33.3)
Severe 28 (12.3) 14 (58.3) 21 (9.5) 7 (46.7)
DNA Ploidy
Diploid 183 (80.3) 10 (41.7) 180 (82.2) 7 (46.7)
Tetraploid 3 (1.3) 0 (0) 3 (1.4) 0 (0)
Aneuploid 42 (18.4) 14 (58.3) 36 (16.4) 8 (53.3)
Table 2. Characteristics of study population, dysplasia grade and DNA ploidy diagnosis.
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There was a significant association between grade of dysplasia and DNA ploidy status (Pearson x2 = 73.3, 
df = 3, p < 0.001). Sixteen of 28 cases with severe dysplasia were aneuploid (57.1%) and the remainder were dip-
loid (12/28 = 42.9%). Approximately three quarters of the mildly dysplastic epithelial lesions (74.5%) were dip-
loid. The DNA ploidy diagnoses by subgroup are shown in Table 2 and the association between ploidy diagnosis 
and dysplasia grade in Table 3.
Dysplasia and malignant transformation. Among the 24 (10.5%) of 228 patients who developed car-
cinoma including those with transformation less than 6 months from index lesion, more than half (58.3%) had 
severe dysplasia. The mean transformation time was 1.95 years (SD = 2.09). Dysplasia diagnoses by subgroup are 
shown in Table 2.
In the one case excluded from Kaplan-Meier and Cox regression analyses because of carcinoma synchronous 
with the worst dysplasia grade, prior biopsies had been aneuploid 8 months before transformation. Adjusting 
for age and sex, Kaplan-Meier curves of progression-free estimates in Fig. 2 shows that the time to malignant 
transformation was significantly shorter in the severely dysplastic group (log rank: x2 = 76.25, df = 3, p < 0.0001).
Hazard ratios were highly significant (p < 0.001) indicating the risk of a severely dysplastic lesion developing 
carcinoma was 81.8 (95% CI 10.5, 635.9) times higher than for a non-dysplastic lesion (Table 4). Multivariate 
analysis was conducted incorporating all grades of dysplasia and ploidy adjusted for age and gender, and showed 
that the hazard ratio for severe dysplasia was lower at 54.25 (95% CI 6.6, 448.2) but remained highly significant 
(p < 0.001).
Excluding patients with transformation within 6 months of the index biopsy (n = 219), the number of cases 
that underwent malignant transformation was lower at 15 in a mean time of 3.03 years (SD = 1.96). One patient 
(6.7%) with a non-dysplastic lesion and 2 (13.3%), 5 (33.3%), 7 (46.7%) patients with mild, moderate and severely 
dysplastic epithelium respectively had undergone malignant transformation.
Patients with higher grades of dysplasia developed carcinoma more rapidly (log rank: x2 = 40.28, df = 3, 
p < 0.0001, Fig. 2). Although the hazard ratios for moderate and severe dysplasia decreased to 21.6 (95% CI 2.49, 
186.8) and 45.8 (95% CI 5.52, 379.6) respectively when compared to the univariate analysis that included early 
transformation, they remained highly significant with p ≤ 0.005 (Table 4).
Multivariate analysis incorporating all grades of dysplasia and ploidy, adjusted for age and gender showed that 
the hazard ratio for severe dysplasia was lower at 30.56 (95% CI 3.37, 277.4) when compared to univariate analy-
sis. The p-value was slightly higher than in the univariate analysis, however still significant (p < 0.05). Multivariate 
analysis proved impossible for smoking and oral subsite though lack of accurate data, which carries some risk of 
bias.
DNA ploidy and malignant transformation. In the complete patient group, including those with malig-
nant transformation within 6 months of the index biopsy, 14 (58.3%) aneuploid and 10 (41.7%) diploid lesions 
progressed to carcinoma (Table 2) in a mean time of 2.05 years (SD = 2.01). The risk of malignant transformation 
was 7.92 times higher (95% CI 3.45, 18.17) in aneuploid than diploid lesions (p < 0.001) (Table 4). Patients with 
aneuploid lesions developed cancer more rapidly than those with diploid lesions (log rank: x2 = 33.15, df = 2, 
p < 0.0001) (Fig. 2).
Excluding patients with transformation within 6 months of the index biopsy (n = 219), 8 (53.3%) patients 
with aneuploid and 7 (46.7%) diploid lesions underwent malignant transformation (Table 2). The mean transfor-
mation time was 3.05 year (SD = 1.93). The hazard ratio for a patient with an aneuploid result was 6.79 (95% CI 
2.56, 17.9) and was highly significant (p < 0.001) compared to patients with diploid lesions (Table 4). Patients 
with aneuploid index lesions developed carcinoma in a shorter time than diploid (log rank: x2 = 17.88, df = 2, 
p = 0.0001) (Fig. 2).
In multivariate analysis, the hazard ratio for patients with aneuploid lesions was 2.41(95% CI 0.89, 6.52) and 
2.39 (95% CI 0.72, 7.98) when transformation of less than 6 months was included and excluded in the analysis, 
respectively (Table 4) and these were not statistically significantly different.
DNA ploidy
Dysplasia n (%)
Total n (%)None Mild Moderate Severe
Diploid 120 (65.6) 35 (19.1) 16 (8.7) 12 (6.6) 183 (100.0)
Tetraploid 1 (33.3) 1 (33.3) 1 (33.3) 0 (0.0) 3 (100.0)
Aneuploid 0 (0.0) 11 (26.2) 15 (35.7) 16 (38.1) 42 (100.0)
Total n (%) 121 (53.1) 47 (20.6) 32 (14.0) 28 (12.3) 228 (100.0)
DNA ploidy
Dysplasia n (%)
Total n (%)
None Mild Moderate Severe
Diploid 120 (99.2) 35 (74.5) 16 (50.0) 12 (42.9) 183 (80.26)
Tetraploid 1 (0.8) 1 (2.13) 1 (3.1) 0 (0.0) 3 (1.32)
Aneuploid 0 (0.0) 11 (23.40) 15 (46.9) 16 (57.1) 42 (18.4)
Total n (%) 121 (100.0) 47 (100.0) 32 (100.0) 28 (100.0) 228 (100.0)
Table 3. Distribution of DNA ploidy diagnosis by degree of dysplasia in all samples. Upper table shows number 
and % of total with each DNA ploidy result and lower table number and % of each dysplasia grade.
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Annual transformation rate. Annual malignant transformation rates for dysplasia grading and DNA ane-
uploidy are shown in Table 5. For dysplasia grade, total person-year of follow up was 1733.07 and 1731.64 when 
transformation within 6 months was included and excluded yielding annual rates of 1.32% and 0.87% respec-
tively. Transformation rates increased with the severity of dysplasia. When transformation within 6 months of 
Figure 2. Kaplan Meier curves for malignant transformation. Upper panel. Progression-free proportion by 
dysplasia grade including (left) and excluding (right) malignant transformation within 6 months of diagnosis 
of the index lesion (dysplasia grades green, none; blue, mild; amber, moderate; red, severe). Lower panel. 
Progression-free proportion by DNA ploidy status including (left) and excluding (right) transformation within 
6 months of diagnosis of the index lesion (ploidy diagnosis green, diploid; blue, tetraploid; red, aneuploid). The 
number of patients still at risk at selected time points (x-axis) is shown below each plot. The difference in time to 
progression for different grades and DNA ploidy status were statistically significant, log rank test p ≤ 0.001.
Including transformation within 6 months of index lesion 
(n = 228)
Excluding transformation within 6 months of index lesion 
(n = 219)
n
Univariate Multivariate
n
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
DYSPLASIA
No 121 1.00 — 1.00 — 121 1.00 — 1.00 —
Mild 47 5.13 (0.46, 56.6) 0.182 3.81 (0.33, 43.96) 0.284 47 5.03 (0.46, 55.7) 0.187 3.90 (0.33, 45.4) 0.278
Mod 32 29.64 (3.6, 243.6) 0.002 18.78 (2.1, 167.9) 0.009 30 21.57 (2.49, 186.8) 0.005 14.11 (1.45, 137.3) 0.023
Sev 28 81.82 (10.5, 635.9) 0.000 54.25 (6.6, 448.2) 0.000 21 45.79 (5.52, 379.6) 0.000 30.56 (3.37, 277.4) 0.002
DNA PLOIDY
Dip 183 1.00 — 1.00 — 180 1.00 — 1.00 —
An 42 7.92 (3.45, 18.17) 0.000 2.41 (0.89, 6.52) 0.083 36 6.79 (2.56, 17.9) 0.000 2.39 (0.72, 7.98) 0.155
Table 4. Cox proportional hazards model on association of dysplasia grade and ploidy status with malignant 
progression. HR: hazard ratio. Univariate: adjusted for age, sex. Multivariate: adjusted for age, sex and 
mutually adjusted between dysplasia grade and ploidy status. Mod = moderate; Sev = severe; Dip = diploid; 
An = aneuploid.
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index lesion was excluded, the rates were 0.09% for the non-dysplastic lesion, 0.53% for mild, 2.68% moderate 
and 5.77% for severe dysplasia. Annual malignant transformation rates for ploidy calculated with inclusion and 
exclusion of malignant transformation within 6 months were 1.38% and 0.87% cases per year respectively. By 
analyzing cases of dysplasia only, the transformation rate was slightly higher at 3.2% and 2.04% cases per year 
when early transformation was either included or excluded respectively.
Predictive values. The number of patients in the tetraploid group was too small for analysis, therefore pre-
dictive values were calculated combining diploid and tetraploid groups, justified on the basis of previous analy-
sis26. Results for combinations of dysplasia grade and DNA ploidy status are shown in Table 6.
Including malignant transformation less than 6 months from index lesion, the positive predictive value (PPV) 
for severe dysplasia was 50% (95% CI 31.5, 68.5) and 33.3% (95% CI 19.0, 47.6) for aneuploid lesions. When 
lesions with both DNA aneuploidy and severe dysplasia were combined, the PPV was increased to 56.3% (95% CI 
31.9, 80.6). Diploid or tetraploid and non-dysplastic lesions had high negative predictive values (NPV) of 94.6% 
(95% CI 91.4, 97.8) and 99.17% (95% CI 97.4, 100.8) respectively.
Excluding cases with transformation within 6 months of index lesion (Table 6), the PPV was reduced to 33.3% 
(95% CI 13.1, 53.5) and 22.2% (95% CI 8.6, 35.8) for severe dysplasia and DNA aneuploidy respectively. When 
lesions with both DNA aneuploidy and severe dysplasia were combined, the PPV was slightly increased to 36.4% 
(95% CI 7.9, 64.8). The NPV of diploid or tetraploid was 96% (95% CI 93.4, 99.0) and 99% (95% CI 97.4, 100.8) 
for non-dysplastic lesions.
Site specificity. No meaningful analysis of site specificity was possible. ICD coded site data from cancer 
registration for these years often lacked laterality. Local pathology databases contained cancer site data for 7 
patients. In broad terms, sites of index biopsy appeared to be at the site of cancer development in 5 patients (2 
lateral tongue, 2 floor of mouth and 1 buccal). In one patient the index biopsy was from floor of mouth and carci-
noma developed on the lateral tongue. In one patient, the cancer was remote from the biopsy site (alveolar ridge 
in opposing jaw). While the descriptions recorded appear to show cancer developing in the same site as index 
biopsy in 5 cases, each of these sites covers several cm2 and site cannot be matched within a few millimetres. This 
and the small numbers prevent analysis of site specificity.
Discussion
Prevention of oral squamous carcinoma in patients with OPMD requires an accurate assessment of the risk of 
malignant transformation to target treatment appropriately. The standard test of grading dysplasia histologically 
in a biopsy has limitations. It is moderately effective when changes are severe but in many studies has been shown 
to have too low a positive predictive value8,9,27 so that grade is generally considered a poor predictor of transfor-
mation. In this study, the additional value of ploidy analysis over dysplasia grading may appear limited because 
dysplasia grading has proved a good predictor in our centre. However, in the broader context of the many studies 
showing poor prediction, we hypothesise that DNA ploidy analysis could prove to be the best predictor in centres 
where dysplasia grade is poorly correlated with outcome.
DNA ploidy analysis has potential as a more objective technique. Unlike conventional ploidy analysis that 
determines chromosome number, DNA ploidy analysis measures only total DNA content in individual nuclei. 
This parameter is frequently abnormal in malignant neoplasms and precancerous conditions as a result of chro-
mosomal instability and missegregation during mitosis and has been used in a variety of clinical settings28. 
Including transformation within 6 months of index 
lesion
Excluding transformation within 6 months of index 
lesion
n
Number 
transformed
Person-
years 
follow up
Annual 
transformation 
rate % (95% CI) n
Number 
transformed
Person-
years 
follow up
Annual 
transformation 
rate % (95% CI)
Dysplasia grade
No 121 1 1045.02 0.09(0.01, 0.68) 121 1 1045.02
0.09
(0.01, 0.68)
Mild 47 2 378.85 0.53(0.13, 2.11) 47 2 378.85
0.53
(0.13, 2.11)
Mod 32 7 187.08 3.74(1.78, 7.85) 30 5 186.49
2.68
1.11, 6.44
Sev 28 13 122.13 10.64(6.18, 18.33) 21 7 121.29
5.77
(2.75, 12.11)
All 228 23 1733.07 1.32(0.88, 1.99) 219 15 1731.64
0.87
(0.52, 1.44)
DNA Ploidy
Dip 183 10 1478.24 0.68(0.36, 1.26) 180 7 1476.69
0.47
(0.23, 0.99)
Tet 3 0 22.68 0 3 0 22.68 0
An 42 14 234.31 5.97(3.54, 10.1) 36 8 232.55
3.44
(1.72, 6.88)
All 228 24 1735.23 1.38(0.93, 2.06) 219 15 1731.93
0.87
(0.52, 1.44)
Table 5. Dysplasia grade- and DNA ploidy-specific annual transformation rates. Mod = moderate; 
Sev = severe; Dip = diploid; Tet = tetraploid; An = aneuploid.
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Analysis using image-based systems, as in this work, has advantages of being able to identify specific small areas 
of interest for analysis and the ability to separate DNA measurements from different types of cells accurately to 
provide an internal control.
Previous studies on DNA ploidy analysis by others have been small series with a case-control design15,16 or 
included leukoplakia only17,18. We have previously tested DNA ploidy in a large series of patients with OPMD and 
conditions with which OPMD are frequently confused clinically26. In this relatively low risk population including 
all red and white lesions raising suspicion of an OPMD referred from primary care, DNA ploidy analysis proved 
as effective as dysplasia grading, had a high negative predictive value to exclude lesions with no risk and was able 
to identify risk in lesions that appeared innocuous on dysplasia grading. However, that study had limitations. It 
was not possible to perform DNA ploidy analysis on every sample, and some selection bias was likely to favour 
analysis of larger lesion with greater sample size. The study evaluated a hospital referral population with an over-
all low risk of transformation, but the predictive value might be higher in a population that have been screened 
clinically and would be at higher risk. The positive predictive value of DNA ploidy analysis would normally be 
expected to rise with a higher incidence of malignant transformation, but the only comparable study showed a 
similar positive predictive value and low negative predictive value16, possibly because of the high transformation 
rate in the hospital-based sample.
In the present study we have addressed these various issues. The nuclear separation technique required only 
half as much tissue as the previous protocol, produced equivalent quality samples as assessed by diploid peak 
INCLUDING 6 MONTHS 
INDEX BIOPSY
EXCLUDING 6 MONTHS INDEX 
BIOPSY
PPV % (95 CI) NPV % (95 CI) PPV % (95 CI) NPV % (95 CI)
Total patients N = 228 N = 219
DYSPLASIA GRADE
None 0.83(−0.8, 2.4)
99.17
(97.4, 100.8)
0.83
(−0.8, 2.4)
99.17
(97.4, 100.8)
Mild 4.26(−1.5, 9.9)
95.74
(89.9, 101.5)
4.26
(-1.5, 9.9)
95.74
(89.9, 101.5)
Mod 21.88(7.5, 36.1)
78.12
(63.8, 92.4)
16.67
(3.4, 30.0)
83.33
(70.0, 96.6)
Sev 50.0(31.5, 68.5)
50.0
(31.5, 68.5)
33.33
(13.1, 53.5)
66.67
(46.5, 86.9)
DNA PLOIDY
Dip or Tet 5.38(2.1, 8.5)
94.62
(91.4, 97.8)
3.83
(1.0, 6.6)
96.17
(93.4, 99.0)
An 33.33(19.0, 47.6)
66.67
(59.9, 73.5)
22.22
(8.6, 35.8)
77.78
(64.2, 91.4)
COMBINATIONS
Ploidy Operator Dysplasia
Dip or Tet AND No — 99.2(97.6, 100.8) —
99.2
(97.6, 100.8)
Dip or Tet AND No OR Mild — 98.1(95.9, 100.2) —
98.1
(95.9, 100.2)
Dip or Tet AND Any grade — 94.6(91.4, 97.9) —
96.2
(93.4, 99.0)
Dip or Tet OR No — 94.6(91.4, 97.9) —
96.2
(93.4, 99.0)
Dip or Tet OR No OR Mild — 94.9(91.9, 98.0) —
96.4
(93.8, 99.0)
Dip or Tet OR Any grade — 89.5(85.5, 93.5) —
93.2
(89.8, 96.5)
An AND Sev 56.3(31.9, 80.6) —
36.4
(7.9, 64.8) —
An AND Sev OR Mod 45.2(27.6, 62.7) —
32.0
(13.7, 50.3) —
An AND Any grade 33.3(19.1, 47.6) —
22.2
(8.6, 35.8) —
An OR Sev 35.2(22.4, 47.9) —
23.9
(11.6, 36.2) —
An OR Sev OR Mod 29.2(18.7, 39.7) —
19.4
(9.5, 29.2) —
An OR Any grade 21.5(13.7, 29.3) —
14.3
(7.4, 21.2) —
Table 6. Positive and negative predictive value of combined dysplasia grading and DNA ploidy. PPV = positive 
predictive value; NPV = negative predictive value. Mod = moderate; Sev = severe; Dip = diploid; Tet = tetraploid; 
An = aneuploid.
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CV, and extracted a larger number of nuclei for more accurate determination of 5c and 9c exceeding rates29. This 
enabled analysis of a more representative near sequential series of patients. Patient inclusion involved excluding 
as far as possible low risk lesions on the basis of clinical descriptors (including age, site, size, multifocality, colour, 
nodularity, verrucous morphology and habits when available) and biopsy result. Conditions such as lichen planus 
and chronic hyperplastic candidosis of no risk or minimal risk that were included in our previous study were 
excluded. Patients were included after examination by a clinician specialising in OPMD whereas in our previous 
study they were included after referral from primary care. The current study population is more representative of 
patients who are retained for follow up in hospital clinics after clinical and pathological assessment.
As in our previous study, we have analysed outcome for dysplasia grades and DNA ploidy diagnosis in sub-
groups with and without transformation within 6 months of the index lesion. Early transformation is considered 
to reflect sampling error in biopsy and failure to detect a carcinoma that may already have been present. The 
knowledge that some test results might indicate this very high risk is valuable clinically, and including this group 
provides the predictive values of most use to clinical practice. It is not possible to comment on whether these early 
transforming cases did have concurrent carcinoma, but if so it was not appreciated clinically and did not become 
evident in 6 months. Conversely, analysis with early transformation excluded provides a better reflection of the 
natural history of OPMD and analysis of this subgroup reflects provides predictive values useful for longer term 
surveillance. The distributions of age, gender, prevalence and grades of dysplasia, and presence of aneuploidy 
are comparable to other similar studies, whether early transformation is included or not15–18,26. In this series, 
carcinomas arising in mild and moderate dysplasia arose in the first 2 years of follow up, while those arising in 
severe dysplasia continued to develop throughout the 9.6 years study duration, consistent with older dysplasia 
studies6,14,30,31 and our and others more recent analyses26,32. It is clear that both dysplasia grading and DNA ploidy 
abnormality indicate long term risk.
We have confirmed the significant correlation between DNA ploidy status and dysplasia shown in our and 
other previous reports15,16,20,21,26 with approximately 40% of DNA abnormal lesions being severely dysplastic and 
none of the non-dysplastic lesions were aneuploid. However, as previously, many severely dysplastic lesions are 
DNA diploid at the threshold diagnostic criteria used. As the positive predictive value of dysplasia exceeds that of 
aneuploidy alone, severely dysplastic but DNA diploid lesions sometimes transform and this raises the possibility 
that more sensitive diagnostic criteria or higher definition analysis techniques might identify these extra cases at 
risk.
It can also be concluded that ICM DNA ploidy has value in identifying high risk lesions from among appar-
ently innocuous low risk cases with only mild dysplasia, because 23% of lesions with mild dysplasia harboured 
aneuploidy. However, the risk in this population appears lower than in higher grade dysplasia with aneuploidy, 
or possibly develops over a longer period, as neither of the two lesions with mild dysplasia that transformed were 
aneuploid. However, numbers are too low to analyse this meaningfully.
When evaluating the value of DNA ploidy analysis against dysplasia grading, it is important to note that most 
studies have failed to show a good correlation between dysplasia grade and malignant transformation9. This and 
our previous study26 show relatively good predictive values for dysplasia grading, based on the original diagnostic 
dysplasia grade made by consensus of two pathologists views, with a third opinion sought in the event of disagree-
ment, as more recently suggested to be best practice33.
We have again shown that each grade remains statistically significantly different, even when DNA ploidy was 
considered simultaneously and whether or not early transformation was included. Despite results from several 
other large studies8,9,27 and the negative tone of much of the literature, we therefore support dysplasia grading as a 
strong independent indicator of malignant transformation and this is supported by meta-analysis4,34.
This study confirms that DNA ploidy analysis predicts malignant transformation. This agrees with our pre-
vious analysis of a more diverse low risk series of lesions26 and firmly establishes DNA ploidy analysis as a useful 
clinical test. Others have found more variable results, one similar study reporting similar findings18 while others 
reported a lower hazard ratio17, these differences probably largely accounted for by differences in study popula-
tion with differing risks of transformation.
It is not possible to determine whether DNA ploidy might have predictive superiority over traditional dyspla-
sia as a single test to predict malignant transformation, partly because the value of dysplasia grading is so con-
tentious. In the present study, where dysplasia grading performed well and transformation rates were calculated 
on an individual patient basis, the statistical significance of DNA aneuploidy was lost when dysplasia grade was 
considered simultaneously in multivariate analysis and we suggest that DNA ploidy results should be considered 
an additional source of useful predictive information to predict outcome and combined with other established 
parameters.
In this series, severe dysplasia but not moderate dysplasia was a better predictor of malignant transformation 
than ICM DNA aneuploidy. Both absence of dysplasia and ICM DNA diploid status had an equivalent positive 
and negative predictive value, whether or not early transformation was included in the analysis. While this sug-
gests no advantage to DNA ploidy, our results for dysplasia grading are considerably better than most published 
studies and we hypothesise that DNA ploidy analysis would have great potential where grading is less effective. 
Even in the present study DNA ploidy analysis identified DNA aneuploidy in almost a quarter of lesions that 
showed only mild dysplasia, and these patients would normally be discharged from hospital care.
In the present work, we have been able to combine results from dysplasia grading and DNA ploidy analysis. 
The combination of severe dysplasia and ICM DNA aneuploidy has increased predictive value over both aneu-
ploidy and severe dysplasia alone and a similar relationship holds with moderate dysplasia. In contrast, adding 
diploid or tetraploid to the absence of dysplasia showed no benefit to the negative predictive value. However, one 
of the most valuable aspects of DNA ploidy analysis remains the ability to exclude risk in low risk lesions with 
more confidence, enabling patients to be discharged for follow up in primary care, avoiding financial cost, incon-
venience and repeated biopsy.
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In conclusion, the results of this study provide additional evidence that DNA ploidy analysis is a good predic-
tor of malignant transformation in OPMD when applied to oral lesions assessed as having a risk of transformation 
on clinical grounds. The results also complement the sparse data supporting the efficacy of dysplasia grading 
to predict malignant transformation in routine clinical practice. The highest predictive values are produced by 
combinations of the two techniques and the predictive values reported here exceed those from published studies 
to date. DNA ploidy analysis has value in patient management, both to detect high risk lesions and confidently 
identify those with no risk.
Methods
This work complies with UK guidelines and legislation. The study was approved by the Guy’s Hospital Research 
Ethics Committee and the use of material and data without individual consent has been specifically approved by 
the UK Patient Information Advisory Group [reference PIAG 4-09(f)2003].
Case and sample selection. Pathology reports and original request forms for specimens submitted 
between 2004 and 2007 were searched by hand from the archive of the Department of Oral Pathology, King’s 
College London. Inclusion criteria were cases with diagnosis of dysplasia confirmed histopathologically or, if 
non-dysplastic with a clinical description provided by the clinician either as leukoplakia, erythroplakia, white 
patch/lesion or red patch/lesion or mixed white and red patch/lesion, and a clinical assessment indicating risk of 
transformation clinically. Histological diagnosis of dysplasia was made by consensus of two pathologists based 
on WHO criteria at the time of diagnosis, with more emphasis on architectural features than in the WHO 2005 
definition. The dysplasia grading was directly equivalent to the WHO 2017 three grade system.
Exclusion criteria were a histological diagnosis, clinical diagnosis or clinical suspicion of any benign red or 
white oral lesion including candidosis, frictional keratosis, lichenoid reactions or lichen planus. Three patients 
with a clinical description including striae were included but these also had plaque type lesions and no evidence 
of lichenoid changes histologically. Patients with prior history of oral squamous carcinoma, carcinoma in first 
biopsy or in a second biopsy within 2 weeks were excluded. Follow-up data was acquired from cancer registra-
tions and local pathology database, which showed complete concordance, and causes of death data from the 
Health and Social Care Information Centre. All oral biopsy specimens for the patient within the time frame were 
identified for analysis and all request forms and records checked for exclusion criteria.
Preparation of nuclear monolayers. Paraffin blocks were subgrouped into specimens suitable for routine 
conventional preparation, or smaller samples more suited to a novel method of monolayer preparation, based on 
the amount of tissue available.
The conventional procedure was performed as described previously26. Briefly, multiple sections 50 µm thick 
equivalent to at least 50 mm total epithelial length were cut, deparaffinized in xylene, rehydrated in ethanols to 
cold PBS and then incubated in 2 mls 0.05% protease type XXIV (Sigma) at 37 °C in a high speed shaking water 
bath at 250 rpm for 90 minutes. Released nuclei were filtered through 60mesh nylon gauze and cytospun (Thermo 
Shandon Cytospin 4) to disperse a monolayer onto a glass slide.
In the improved method for small samples, sections with only 25 mm epithelial length were deparaffinised and 
rehydrated in the same way and then washed twice in cold PBS by centrifugation for 10 minutes at 1000 rpm and 
2200 rpm35. Tissue was digested in 1 ml 0.5 mg/ml protease solution (Bacillus licheniformis type VIII, Sigma) at 
room temperature on a magnetic stirrer using micro-magnetic stirring bars at 600 rpm for 90 minutes. Released 
nuclei were filtered and monolayers prepared as in the conventional method. Nuclear monolayers were stained 
by the Feulgen-Schiff method. Efficiency of nuclear preparation by the two methods was compared on an inde-
pendent set of 10 samples.
DNA image cytometry. The DNA content of stained nuclei was measured using a PWS (Ploidy Work 
Station) Grabber system (Room4, Sussex UK), comprising an automated scanning Zeiss Axioplan II microscope 
(Zeiss, Oberkochen, Germany) equipped with a 546 nm green barrier filter. Images were captured with a black 
and white AxioCam MRm digital camera (Zeiss, Oberkochen, Germany) with 40x lens providing a resolution for 
analysis of 162 nm per pixel.
Images from a maximum of 3000 nuclei were automatically scanned and images classified into epithelial, 
control (lymphocyte and fibroblast) and debris. The PWS Classifier software (Room 4, Sussex UK) was used to 
discard cut, overlapped and pyknotic nuclei and create DNA ploidy histograms. If cases yielded less than the 300 
epithelial nuclei required for diagnosis, analysis was repeated when possible; otherwise the case was excluded. All 
galleries were edited and all histograms were diagnosed by ZMZ and EWO.
DNA ploidy diagnostic criteria. Histograms were classified according to previous criteria26. A lesion was 
classified as DNA diploid if only one 2c peak (G0/G1) formed by epithelial nuclei was present, the number of 
nuclei at 4c peak (G2) did not exceed 10% of the total number of epithelial nuclei and the number of nuclei with 
DNA content more than 5c did not exceed 1%. A lesion was defined as DNA tetraploid if a 4c peak (DI 1.9–2.1; 
3.8–4.2c) exceeding 10% of the total nuclei was present with no other abnormality. Aneuploid lesions were char-
acterized by the presence of one or more peak(s) containing more than 10% of the epithelial nuclei outside the 
range of the normal diploid (diploid index (DI) 0.9–1.1) or G2 (DI 1.8–2.2c) peaks or when the number of nuclei 
with a DNA content above 5c exceeded 1% of the total number of epithelial nuclei. At least 300 epithelial nuclei 
were assessed and samples with a diploid peak coefficient of variation (CV) greater than 5% were excluded. The 
diploid peak coefficient of variation (ratio of standard deviation to mean of DNA content for all nuclei in the 
peak) defines the detection threshold for a ploidy abnormality as narrower peaks (with low CV) are more readily 
discriminated than broad overlapping peaks. The best achievable CV for this type of material is approximately 1, 
giving a detection limit 1% of a change in DNA content28.
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Statistical analysis. The unit of analysis for malignant transformation was the patient. For univariate and 
multivariate analysis, when a patient had multiple biopsies or specimens, the earliest diagnosis with the most 
abnormal result was used as the index lesion for analysis (‘first-worst’ dysplasia and ‘first-worst’ ploidy)26. When 
no dysplasia or DNA ploidy abnormality was found, the earliest lesion was taken as the index lesion. Such analysis 
provides the most appropriate selection to undertake calculation of annual transformation rates, as opposed to 
average rates.
A single patient was excluded from the dysplasia analysis because the worst grade of dysplasia was diagnosed 
at the same time as the carcinoma. However, lower grades of dysplasia and DNA aneuploidy preceded the carci-
noma allowing the case to be included in the univariate analysis of DNA ploidy. Patients were grouped for sepa-
rate analysis into those who developed a carcinoma after and those who developed carcinoma within 6 months 
of their index lesion.
The endpoint date was defined as one of four outcomes: the date carcinoma developed, the last follow-up date 
when no progression had occurred, the date of death if the patient had died of oral carcinoma or the date of death 
from any other cause.
The association between ploidy diagnosis and dysplasia grade was calculated using the Pearson chi-square 
test. Kaplan-Meier methods were used to estimate the time to progression and percentage of patients who under-
went malignant transformation by dysplasia and ploidy diagnosis. Survival curves were compared using the log 
rank test. Cox regression methods were used to investigate the main independent predictors of malignant trans-
formation. Adjusting for age and gender, each dysplasia grade and ploidy result category was assessed separately 
in a univariate Cox proportional hazards model. In the multivariate model, adjustment involved age, sex and 
mutual adjustment between dysplasia grade and ploidy status. Hazard ratios (HR) with 95% confidence interval 
(95% CI) and p values were reported and p < 0.05 was considered statistically significant. Positive and negative 
predictive values, sensitivity and specificity were calculated from 2 × 2 tables with malignant transformation as 
reference (‘gold standard’). Annual malignant transformation rates were calculated based on actual person-years 
of follow up in order to take into account the time to transformation.
Comparison between conventional and novel methods for nuclear extraction was made using the Wilcoxon 
signed rank test. The reproducibility of DNA ploidy diagnosis was evaluated by using Cohen’s kappa coefficient. 
P-values < 0.05 were regarded as statistically significant.
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